Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment
Purpose: To evaluate the long-term outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) drugs with a pro re nata (PRN) regimen for the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS).Methods: This is a retrospective, multicenter, noncomparative case series of consecutive AS eyes affected by treatment-na ïve CNV. A complete ophthalmologic examination was performed every 30-45 days after the loading phase, including fluorescein angiography and/or optical coherence tomography.Results: In all, 52 eyes of 39 patients were treated with intravitreal bevacizumab and/or rani...
Source: Ophthalmologica - June 22, 2017 Category: Opthalmology Source Type: research

Association of the < b > < i > CFH < /i > < /b > Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population
Aim: Evidence of the relationship between the polymorphism of the complement factor H (CFH) gene at position 402 (Y402H) and the response to the treatment of wet AMD is controversial. The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with theCFH Y402H polymorphism in the Brazilian population.Methods: Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included. The evolution of best-corrected visual acuity (BCVA) and central retinal thickness (...
Source: Ophthalmic Research - June 22, 2017 Category: Opthalmology Source Type: research

Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
CONCLUSIONS: Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. There is moderate-certainty evidence that aflibercept confers some advantage over ranibizumab and bevacizumab in people with DMO at one year in visual and anatomic terms. Relative effects among anti-VEGF drugs at two years are less well known, since most studies were short term. Evidence from RCTs may not apply to real-world practice, where people in need of antiangiogenic treatment are often under-treated and under-monitored.We found ...
Source: Cochrane Database of Systematic Reviews - June 22, 2017 Category: General Medicine Authors: Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E Tags: Cochrane Database Syst Rev Source Type: research

Identification of time point to best define ‘ sub-optimal response ’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data
Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data Eye advance online publication, June 16 2017. doi:10.1038/eye.2017.111 Authors: I Chatziralli, M Santarelli, N Patrao, L Nicholson, M Zola, R Rajendram, P Hykin & S Sivaprasad (Source: Eye)
Source: Eye - June 16, 2017 Category: Opthalmology Authors: I Chatziralli M Santarelli N Patrao L Nicholson M Zola R Rajendram P Hykin S Sivaprasad Source Type: research

Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema
mpeslidis (Source: Eye)
Source: Eye - June 16, 2017 Category: Opthalmology Authors: V E Konidaris K T Tsaousis Z Al-Hubeshy K Pieri J Deane T Empeslidis Source Type: research

Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study
The correlation between the short- and long-term effects of intravitreal ranibizumab (IVR) on macular edema after branch retinal vein occlusion (BRVO) remains unclear. We assessed the correlation between the s... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - June 13, 2017 Category: Opthalmology Authors: Yoshiro Minami, Taiji Nagaoka, Akihiro Ishibazawa and Akitoshi Yoshida Source Type: research

Therapeutic Potential of Ranibizumab in Corneal Neovascularization
Publication date: Available online 9 June 2017 Source:Trends in Pharmacological Sciences Author(s): Marianne L. Shahsuvaryan Ranibizumab is a humanized, affinity-matured vascular endothelial growth factor (VEGF) antibody fragment that neutralizes all isoforms of VEGF and is FDA approved for use in ophthalmology. Recently it was suggested that ranibizumab may be useful in the treatment of corneal neovascularization, but in reality this therapy is not yet evidence based. (Source: Trends in Pharmacological Sciences)
Source: Trends in Pharmacological Sciences - June 10, 2017 Category: Drugs & Pharmacology Source Type: research

Comparative Retinal Vessel Size Study of Intravitreal Ranibizumab and Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration
Conclusion: These results suggest that intravitreal ranibizumab led to significant retinal arteriolar vasoconstriction in eyes with neovascular AMD.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - June 9, 2017 Category: Opthalmology Source Type: research

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
CONCLUSION: IVZ increased the treatment free interval in non-responders but no significant change in visual and anatomic outcomes. PMID: 28596286 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - June 8, 2017 Category: Opthalmology Authors: Braimah IZ, Agarwal K, Mansour A, Chhablani J, Ziv-aflibercept Study Group Tags: Br J Ophthalmol Source Type: research

[Results of Re-switch from Intravitreal Aflibercept to Ranibizumab in Patients with Exudative Age-related Macular Degeneration].
Conclusions A re-switch from aflibercept to ranibizumab may enable improvement in morphological parameters and stabilization of VA in patients with exudative age-related macular degeneration who achieved no more benefit from the initial switch. PMID: 28575913 [PubMed - as supplied by publisher] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - June 3, 2017 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy.
Authors: Matušková V, Balcar VJ, Khan NA, Bonczek O, Ewerlingová L, Zeman T, Kolář P, Vysloužilová D, Vlková E, Šerý O Abstract BACKGROUND: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and ...
Source: Ophthalmic Genetics - June 1, 2017 Category: Opthalmology Tags: Ophthalmic Genet Source Type: research

Management of neovascular glaucoma with intravitreal ranibizumab, panretinal photocoagulation, and subsequent 5-fluorouracil augmented trabeculectomy: A case report
We report a case with neovascular glaucoma due to central retinal vein occlusion who received combination therapy with intravitreal ranibizumab (IVR) injection, panretinal photocoagulation (PRP) and subsequent 5-fluorouracil (5-FU) augmented trabeculectomy. Outcomes: One week after IVR injection, the intraocular pressure (IOP) had partially decreased to 33 mmHg, and there was a complete regression of neovascularization of the iris (NVI) and the angle (NVA). PRP was feasible after IVR due to improvement of corneal edema which made an adequate view of the posterior pole of fundus. The surgery of trabeculectomy with 5-FU was...
Source: Medicine - June 1, 2017 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Long-term in vitro functional stability of compounded ranibizumab and aflibercept.
CONCLUSION: Compounding of ranibizumab and aflibercept in plastic syringes with storage for up to 4 weeks does not appear to have a detrimental effect on the in vitro functional activity of these medications. Because the cost of these medications can be prohibitive, compounding may be considered as a method of reducing cost. PMID: 28576208 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - June 1, 2017 Category: Opthalmology Authors: Cao S, Cui J, Matsubara J, Forooghian F Tags: Can J Ophthalmol Source Type: research

Diabetic Retinopathy Changes With Aflibercept, Bevacizumab, Ranibizumab
This cohort study compares changes in diabetic retinopathy severity after participants have received 1 and 2 years of treatment with aflibercept, bevacizumab, or ranibizumab. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - June 1, 2017 Category: Opthalmology Source Type: research

Cost-effectiveness of Intravitreous Ranibizumab vs Panretinal Photocoagulation
This secondary analysis of a randomized clinical trial evaluates incremental cost-effectiveness ratios of 0.5-mg ranibizumab therapy vs PRP for PDR. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - June 1, 2017 Category: Opthalmology Source Type: research

Diabetic Retinopathy and Antivascular Endothelial Growth Factor Agents
The exploratory analysis performed by Bressler et al in this issue ofJAMA Ophthalmology expounds on the already compelling results from the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T study. Protocol T provided crucial data comparing the 3 most commonly used antivascular endothelial growth factor (VEGF) agents in the management of diabetic macular edema. The authors use the 2-year prospective data on diabetic macular edema treatment to compare the relative efficacy of aflibercept, ranibizumab, and bevacizumab on another clinically relevant end point: diabetic retinopathy (DR) severity. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - June 1, 2017 Category: Opthalmology Source Type: research

Ranibizumab and Panretinal Photocoagulation in Proliferative Diabetic Retinopathy
This Research Letter compares treatment with intraviterous ranibizumab with undergoing panretinal photocoagulation for managing proliferative diabetic retinopathy. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - June 1, 2017 Category: Opthalmology Source Type: research

In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System.
CONCLUSIONS: The current study demonstrates that the DDS can effectively decrease laser-induced CNV lesions in a murine model. Controlled and extended release from our DDS achieved greater treatment efficacy using an order of magnitude less drug than what is required with bolus administration. This suggests that our DDS may provide a significant advantage in the treatment of posterior segment eye diseases. PMID: 28557571 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - May 30, 2017 Category: Opthalmology Authors: Osswald CR, Guthrie MJ, Avila A, Valio JA, Mieler WF, Kang-Mieler JJ Tags: Curr Eye Res Source Type: research

Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - May 30, 2017 Category: Opthalmology Source Type: research

INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial
Purpose: To evaluate aflibercept treat-and-extend regimen for treatment of neovascular age-related macular degeneration in patients with limited response to ranibizumab. Methods: This prospective single-arm trial included 33 patients with neovascular age-related macular degeneration pretreated with treat-and-extend regimen ranibizumab for ≥6 months who failed to be extended to a 6-week interval at least twice. All patients received aflibercept (2 mg/0.05 mL) at baseline, and were subsequently treated according to treat-and-extend regimen, starting with a 4-week interval and extending in 2-week steps. Evaluations includ...
Source: RETINA - May 25, 2017 Category: Opthalmology Tags: Original Study Source Type: research

RESPONSIVENESS OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE-25 TO VISUAL ACUITY GAINS IN PATIENTS WITH DIABETIC MACULAR EDEMA: Evidence From the RIDE and RISE Trials
Conclusion: This exploratory analysis of data from the RIDE and RISE studies supports the responsiveness of the NEI VFQ-25 to changes in best-corrected visual acuity over time in patients with diabetic macular edema. (Source: RETINA)
Source: RETINA - May 25, 2017 Category: Opthalmology Tags: Original Study Source Type: research

Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy.
CONCLUSIONS: The results emphasised the efficacy of anti-VEGF therapy for preserving vision and the limitations of anti-VEGF therapy in that continuous treatment is required over an extended follow-up period. PMID: 28546150 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - May 25, 2017 Category: Opthalmology Authors: Hikichi T Tags: Br J Ophthalmol Source Type: research

[Newly occurring loss of visual acuity in choroidal osteoma].
CONCLUSION: Monitoring is necessary even for primarily benign CO in order to detect secondary complications causing loss of visual acuity, e. g. secondary CNV. Anti-VEGF IVT represents an approved treatment option. PMID: 28540579 [PubMed - as supplied by publisher] (Source: Der Ophthalmologe)
Source: Der Ophthalmologe - May 24, 2017 Category: Opthalmology Authors: Schuh A, Foerster P, Priglinger S, Eibl-Lindner K Tags: Ophthalmologe Source Type: research

Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions
Purpose: To compare the visual and anatomic outcomes of macular edema secondary to retinal vein occlusion after switching from bevacizumab to ranibizumab, aflibercept, or dexamethasone implant.Methods: Fifteen eyes were switched to ranibizumab, 12 to aflibercept, and 10 to dexamethasone. At 3, 6, 9, and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT).Results: One year after the switch, CMT decreased from 430.11 ± 91.21 to 291.86 ± 43.87 μm (p (Source: Ophthalmologica)
Source: Ophthalmologica - May 23, 2017 Category: Opthalmology Source Type: research

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to eit... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - May 23, 2017 Category: Opthalmology Authors: Maria Waizel, Margarita G. Todorova, Michael Masyk, Katharina Wolf, Annekatrin Rickmann, Khaled Helaiwa, Bj örn R. Blanke and Peter Szurman Source Type: research

Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases
Investigate the relationship between best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in eyes receiving ranibizumab for three common retinal diseases. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - May 23, 2017 Category: Opthalmology Authors: William C. Ou, David M. Brown, John F. Payne, Charles C. Wykoff Tags: Original Articles Source Type: research

Relationship Between Visual Acuity and Retinal Thickness During Anti –Vascular Endothelial Growth Factor Therapy for Retinal Diseases
To investigate the relationship between best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in eyes receiving ranibizumab for 3 common retinal diseases. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - May 23, 2017 Category: Opthalmology Authors: William C. Ou, David M. Brown, John F. Payne, Charles C. Wykoff Tags: Original article Source Type: research

Safety and Effectiveness of Cataract Surgery with Simultaneous Intravitreal Anti-VEGF in Patients with Previously Treated Exudative Age-Related Macular Degeneration.
Authors: Falcão MS, Freitas-Costa P, Beato JN, Pinheiro-Costa J, Rocha-Sousa A, Carneiro Â, Brandão EM, Falcão-Reis F Abstract INTRODUCTION: To evaluate the safety and impact on visual acuity, retinal and choroidal morphology of simultaneous cataract surgery and intravitreal anti-vascular endothelial growth factor on patients with visually significant cataracts and previously treated exudative age-related macular degeneration. MATERIAL AND METHODS: Prospective study, which included 21 eyes of 20 patients with exudative age-related macular degeneration submitted to simul...
Source: Acta Medica Portuguesa - May 22, 2017 Category: General Medicine Tags: Acta Med Port Source Type: research

The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat ’s disease
To examined the curative effect of vitreous injection with ranibizumab,laser coagulation and cryotherapy in treating stage 3 Coats ’ disease with exudative retinal detachment. (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - May 22, 2017 Category: Opthalmology Authors: Songfeng Li, Guangda Deng, Jinghua Liu, Yan Ma and Hai Lu Source Type: research

Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor
Conclusion: Idiopathic choroiditis was the most common cause of inflammatory CNV and PRN intravitreal anti-VEGF (ranibizumab or bevacizumab) appears to have effective treatment response. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - May 17, 2017 Category: Opthalmology Authors: Rupak Roy Kumar Saurabh Aditya Bansal Amitabh Kumar Anindya Kishore Majumdar Swakshyar Saumya Paul Source Type: research

[Comment] Gene therapy for the long term treatment of wet AMD
Age-related macular degeneration (AMD) is the most common cause of visual impairment in elderly populations of the developed world,1 and neovascular AMD (wet AMD) accounts for 90% of severe vision loss in patients with AMD. Wet AMD is associated with the upregulation of vascular endothelial growth factor (VEGF), which promotes angiogenesis and vascular permeability.2 Recently, therapies using recombinant anti-VEGF antibody fragments (eg, ranibizumab, bevacizumab, and aflibercept)3 –5 to inhibit VEGF activity have shown that wet AMD can be treated successfully. (Source: LANCET)
Source: LANCET - May 16, 2017 Category: General Medicine Authors: Elizabeth P Rakoczy Tags: Comment Source Type: research

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study.
Conclusions. The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study. PMID: 28491468 [PubMed - in process] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - May 13, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)
L Wickham, D G Charteris, P M Sullivan, E Ezra, Z Gregor, G W Aylward, L da Cruz, D Fabinyi, T Peto, M Restori, W Xing, C Bunce, P G Hykin& J W Bainbridge (Source: Eye)
Source: Eye - May 12, 2017 Category: Opthalmology Authors: O Comyn Source Type: research

Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study)
mp; J W Bainbridge (Source: Eye)
Source: Eye - May 12, 2017 Category: Opthalmology Authors: O Comyn L Wickham D G Charteris P M Sullivan E Ezra Z Gregor G W Aylward L da Cruz D Fabinyi T Peto M Restori W Xing C Bunce P G Hykin J W Bainbridge Source Type: research

Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges
AbstractDiabetic retinopathy (more specifically diabetic macular edema, DME) is the most common cause of loss of vision in the working population in developed countries. Anti-vascular endothelial growth factor (anti-VEGF) agents considerably changed the treatment algorithms and improved prognosis of center-involving DME. Ranibizumab was the first approved anti-VEGF agent that revolutionized DME treatment. The vast increase in the number of patients undergoing intravitreal treatment and the role of anti-VEGF pharmacotherapy as the mainstay of DME treatment have triggered several challenges. Among them, of considerable inter...
Source: Advances in Therapy - May 8, 2017 Category: Drugs & Pharmacology Source Type: research

UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
Abstract AIMS: To compare the effectiveness of continuous aflibercept versus pro re nata (PRN) ranibizumab therapy for neovascular age-related macular degeneration (nAMD). METHODS: Multicentre, national electronic medical record (EMR) study on treatment naive nAMD eyes undergoing PRN ranibizumab or continuous (fixed or treat and extend (F/TE)) aflibercept from 21 UK hospitals. Anonymised data were extracted, and eyes were matched on age, gender, starting visual acuity (VA) and year of starting treatment. Primary outcome was change in vision at 1 year. RESULTS: 1884 eyes (942 eyes in each group) we...
Source: The British Journal of Ophthalmology - May 6, 2017 Category: Opthalmology Authors: Lee AY, Lee CS, Egan CA, Bailey C, Johnston RL, Natha S, Hamilton R, Khan R, Al-Husainy S, Brand C, Akerele T, Mckibbin M, Downey L, Tufail A Tags: Br J Ophthalmol Source Type: research

Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up.
This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD). METHODS: In this retrospective study, 90 nAMD patients' 90 eyes were evaluated. IVR was injected once a month for three consecutive months, and then, patients were followed up for five years by using pro re nata method. RESULTS: Average visual acuity (BCVA) values in TT group for the third, fourth and fifth years were found to be significantly higher than those in TC and CC groups, while average BCVA val...
Source: Ocular Immunology and Inflammation - May 6, 2017 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
Authors: Son BK, Kwak HW, Kim ES, Yu SY Abstract PURPOSE: To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab for the treatment of macular edema associated with branch retinal vein occlusion (BRVO). METHODS: This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patients received either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groups received three initial monthly injections followed by as-needed injections. The best-corrected visual acuity, central subfield thickness, mean number of injections, an...
Source: Korean Journal of Ophthalmology : KJO - May 6, 2017 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab
A systematic review to assess the‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumabEye advance online publication, May 5 2017.doi:10.1038/eye.2017.67Authors: S R Rufai, H Almuhtaseb, R M Paul, B L Stuart, T Kendrick, H Lee& A J Lotery (Source: Eye)
Source: Eye - May 5, 2017 Category: Opthalmology Authors: S R Rufai Source Type: research

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.
Conclusion. Contralateral eyes with ROP can take a different clinical course after ranibizumab treatment. High rate of reactivation after IVR is another concern that ophthalmologists should pay attention to. PMID: 28465833 [PubMed - in process] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - May 5, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research

A systematic review to assess the ‘ treat-and-extend ’ dosing regimen for neovascular age-related macular degeneration using ranibizumab
A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab Eye advance online publication, May 5 2017. doi:10.1038/eye.2017.67 Authors: S R Rufai, H Almuhtaseb, R M Paul, B L Stuart, T Kendrick, H Lee & A J Lotery (Source: Eye)
Source: Eye - May 5, 2017 Category: Opthalmology Authors: S R Rufai H Almuhtaseb R M Paul B L Stuart T Kendrick H Lee A J Lotery Source Type: research

Regarding comments by Mathis T and Kodjikian L on "Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab".
Regarding comments by Mathis T and Kodjikian L on "Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab". Ocul Immunol Inflamm. 2017 May 01;:1 Authors: Parodi MB, Iacono P, Zucchiatti I, Bandello F PMID: 28459297 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - May 3, 2017 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Intravitreal Ranibizumab Injection in Peripapillary CNVM Related to Idiopathic Intracranial Hypertension
Peripapillary choroidal neovascular membrane (CNVM) may develop in papilledema related to idiopathic intracranial hypertension. The authors present a teenaged boy who responded well to one dose of intravitreal ranibizumab injection.[J Pediatr Ophthalmol Strabismus. 2017;54:e27 –e30.] (Source: Journal of Pediatric Ophthalmology and Strabismus)
Source: Journal of Pediatric Ophthalmology and Strabismus - May 2, 2017 Category: Opthalmology Source Type: research

Vascular Safety With Ranibizumab in Diabetic Macular Edema
This cohort study evaluates the safety of ranibizumab compared with sham and laser treatment in patients with diabetic macular edema. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - May 1, 2017 Category: Opthalmology Source Type: research

Two ‐year functional and anatomical results after converting treatment resistant eyes with exudative age‐related macular degeneration to aflibercept in accordance with a treat and extend protocol
Abstract PurposeTo study the effects of converting to aflibercept in accordance with a treat and extend (T&E) strategy in eyes with treatment resistant exudative age‐related macular degeneration (AMD). MethodsTwo‐year prospective study of eyes with exudative AMD and persistent macular fluid despite monthly treatment with ranibizumab or bevacizumab. Eyes were converted to 2.0 mg aflibercept in accordance with a T&E protocol. ResultsFifty eyes from 47 patients were included. At baseline, the mean central retinal thickness (CRT) was 273 μm and mean best‐corrected visual acuity (BCVA) 0.25 logarithm ...
Source: Acta Ophthalmologica - May 1, 2017 Category: Opthalmology Authors: Øystein Kalsnes Jørstad, Rowan Thomas Faber, Morten Carstens Moe Tags: Original Article Source Type: research

Visual outcomes of polypoidal choroidal vasculopathy treated with intravitreal ranibizumab with or without photodynamic therapy
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - April 29, 2017 Category: Opthalmology Authors: Colin S. Tan, Wei Kiong Ngo, Louis W. Lim Tags: Letter to the Editor Source Type: research

Visual outcomes of polypoidal choroidal vasculopathy treated with intravitreal ranibizumab with or without photodynamic therapy
Acta Ophthalmologica,Volume 96, Issue 2, Page e254-e255, March 2018. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - April 29, 2017 Category: Opthalmology Source Type: research

In response to: Parodi MB, Iacono P, Zucchiatti et al. Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab.
This article highlights the efficacy of intravitreal Ranibizumab in the treatment of CNV associated with MEWDS. In our experience, CNV is mostly associated with MEWDS in cases of a wider inflammatory spectrum such as overlapping syndrome with multifocal choroiditis (MFC) or punctuate inner choroidopathy (PIC). The whole pattern of the case presented in the article is compatible with the diagnosis of PIC, meaning that this case described an overlapping between MEWDS and PIC diagnoses. Although the authors wrote that CNV is secondary to MEWDS, another possible hypothesis is that CNV is secondary to PIC. Thus, MEWDS could be ...
Source: Ocular Immunology and Inflammation - April 28, 2017 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema
N V Patrao, J Ramu, C Vazquez-Alfageme, M Muwas, R Rajendram, P G Hykin& S Sivaprasad (Source: Eye)
Source: Eye - April 28, 2017 Category: Opthalmology Authors: L Nicholson Source Type: research

Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema
Sivaprasad (Source: Eye)
Source: Eye - April 28, 2017 Category: Opthalmology Authors: L Nicholson N V Patrao J Ramu C Vazquez-Alfageme M Muwas R Rajendram P G Hykin S Sivaprasad Source Type: research